Fulvestrant |
Faslodex |
Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.[1] It is administered as a once-monthly injection. Fulvestrant is marketed by AstraZeneca with the brand name Faslodex. ...
Wikipedia - [full article]
Resources
- Faslodex (Drug Digest)
- Faslodex Consumer Information (U.S. Food and Drug Administration)
Fulvestrant News Headlines
- New Faslodex(TM) (fulvestrant) Data Fill 'treatment Gap' For Women With Advanced Breast Cancer - Results From A Major Clinical Trial
MedicalNewsToday - Mon, 01 Jan 2007 09:00 EST

Not Signed In -


